Invention Grant
US08685394B2 Combination of anti-CTLA4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
有权
抗CTLA4抗体与多种治疗方案的组合，用于增殖性疾病的协同治疗
- Patent Title: Combination of anti-CTLA4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
- Patent Title (中): 抗CTLA4抗体与多种治疗方案的组合，用于增殖性疾病的协同治疗
-
Application No.: US13384900Application Date: 2009-10-29
-
Publication No.: US08685394B2Publication Date: 2014-04-01
- Inventor: Maria Jure-Kunkel
- Applicant: Maria Jure-Kunkel
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Company
- Current Assignee: Bristol-Myers Squibb Company
- Current Assignee Address: US NJ Princeton
- Agent Stephen C. D'Amico
- International Application: PCT/US2009/062519 WO 20091029
- International Announcement: WO2011/011027 WO 20110127
- Main IPC: A61K39/395
- IPC: A61K39/395
Abstract:
Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders. Such Compositions comprise inter alia an anti-CTLA-4 agent, e.g. ipilimumab or tremelimumab in combination with other chemotherapeutic agents such as dasatinib, imatinib, paclitaxel, gemcitabine, cisplatin or etoposide.
Public/Granted literature
Information query
